TWEAK–Fn14 as a mediator of acute kidney injury  by Weinberg, Joel M.
commentar y
Kidney International (2011) 79    151
 TWEAK (tumor necrosis factor-like weak 
inducer of apoptosis), a type II transmem-
brane protein and member 12 of the tumor 
necrosis factor (TNF) superfamily, was 
discovered in 1997. 1 Its receptor, Fn14, 
a type I transmembrane protein and 
member of the fi broblast growth factor-
inducible gene family, was recognized by 
diff erential display and later identifi ed in 
2001 as the TWEAK receptor. 2,3 TWEAK –
 Fn14 is widely expressed in immune cells 
and in vascular and parenchymal cells of 
multiple tissues and has been implicated 
in both injury and repair via eff ects to pro-
mote infl ammation, cell death, and cellular 
proliferation. 2,3 
 In kidney, Ortiz and co-workers fi rst 
described involvement of TWEAK – Fn14 
in a folate-induced nephropathy model in 
 Kidney International in 2006 4 and have 
followed up on those observations with 
folate and in other models in several sub-
sequent reports. 5 – 7 Expression of message 
and protein for both TWEAK and Fn14 
increases aft er folate, with much larger 
relative changes in Fn14 (14-fold for mes-
sage and 2.5- to 3-fold for protein) than 
for TWEAK (1.5-fold for message and 
1.2-fold for protein). 4 Treatment with an 
anti-TWEAK monoclonal antibody mod-
erately alleviates creatinine increases and 
tubular injury aft er folate and reduces 
induction of mRNA for monocyte chem-
oattractant protein-1 and RANTES, but 
not for interleukin-6. 5 TWEAK knockout 
mice have substantially blunted creatinine 
increases aft er folate as compared with 
wild-type mice. 6 Using other  in vivo mod-
els, Ortiz ’ s group has shown that systemic 
administration of TWEAK to both nor-
mal and hyperlipidemic apolipoprotein E 
knockout mice increases cytokine expres-
sion and nuclear factor-  B-dependent 
interstitial inflammation, while anti-
TWEAK monoclonal antibody retards 
the spontaneous interstitial nephritis that 
develops in the apolipoprotein E knock-
outs. 7 TWEAK knockout mice have a 
diminished acute proliferative response 
to reduction of renal mass by uninephrec-
tomy. 6 TWEAK – Fn14 has been impli-
cated in the pathogenesis of experimental 
lupus nephritis, 8 and increases of urinary 
TWEAK may be useful as a biomarker for 
active human lupus nephritis. 9 Paradoxi-
cally, despite the acute proinfl ammatory 
eff ects of TWEAK, serum TWEAK levels 
are inversely correlated with chronic 
kidney disease mortality 10 and the pres-
ence of coronary artery disease. 11 
 Studies of cultured tubule cells by Ortiz 
and co-workers have shown that TWEAK 
activates nuclear factor-  B and increases 
cytokine production 5,7 as seen in multi-
ple other cell types, 2,3 including mesang-
ial cells and podocytes, in culture. 12 In 
culture, TWEAK promotes tubule-cell 
proliferation under control conditions 6 
but induces apoptosis via the caspase-8-
dependent extrinsic pathway when 
coadministered with TNF-  and inter-
feron-  under conditions in which the 
latter two cytokines do not by themselves 
cause cell death. 4 
 Th us, TWEAK – Fn14 in the kidney, in 
work that tested eff ects of manipulating 
TWEAK availability both by blocking 
antibodies and by genetic deletion, is well 
documented to induce development of a 
proinfl ammatory tubule-cell phenotype, 
and to promote both cellular proliferation 
and apoptosis, depending on the context 
in which the system is activated. The 
observed pattern of TWEAK – Fn14 
upregulation in response to injury of the 
kidney is similar to that in other tissues, 
with small changes in baseline TWEAK 
expression but large relative increases of 
expression of the Fn14 receptor, 2,3 sug-
gesting that the major regulation of the 
response is at the level of the receptor and 
that it may be a particularly useful target 
for intervention. Now, Hotta  et al. 13 (this 
issue) focus on Fn14 and demonstrate an 
important role for TWEAK – Fn14 in the 
commonly used clamp ischemia model of 
acute kidney injury. 
 As in the previous work with folate 
nephropathy, 4 Hotta  et al. 13 show that 
both TWEAK and Fn14 increase in the 
kidney during ischemia – reperfusion, 
with larger relative increases of Fn14 
(16.4-fold maximum mRNA at 6 hours 
of reperfusion and large increase of pro-
tein by immunoblotting) than of TWEAK 
(1.7-fold maximum mRNA at 24 hours 
and no increase of protein by immunob-
lotting). Th ey provide more information 
about localization of these changes than 
do the previous reports, showing 
TWEAK to be present in both uninjured 
and injured tubule cells in the cortex and 
outer medulla, whereas the increases of 
Fn14 are concentrated in the injured 
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tubules of the outer medulla, where dam-
age is most prominent in ischemia – reper-
fusion models. 
 Hotta  et al. 13 report a diffuse cytosolic 
distribution of TWEAK in tubules by 
immunohistochemistry and exclusive 
cytosolic localization on immunoblots 
of subcellular fractions. TWEAK is 
synthesized as a type II transmembrane 
protein and can be active at the cell sur-
face in a juxtacrine fashion. 14 However, 
like TNF-  , most of it is cleaved intra-
cellularly, and a proportion of the 
cleaved form is then secreted. 1 Although 
Hotta  et al. 13 do not indicate whether 
the molecular weight of their TWEAK 
immunoblot signal is consistent with 
the 18-kDa processed form of TWEAK, 
the diffuse cytosolic distribution by 
immunostaining and the cytosolic 
localization by western blotting of cell 
fractions suggest that this is the case. 
Given the apparent luminal localization 
of induced Fn14 in the proximal tubules 
of the outer medulla, TWEAK secreted 
from upstream areas of the proximal 
tubule as well as from immediately 
adjacent cells into the lumen would 
reach and activate it ( Figure 1 ). Fn14 
has the expected membrane localiza-
tion by immunoblotting and was also 
detected in nuclear fractions. By immu-
nohistochemistry, Fn14 appeared to be 
localized to the apical membrane both 
in human biopsies taken 1  h after trans-
plantation and in perfusion-fixed tissue 
from the mouse ischemia – reperfusion 
studies. Toll-like receptor 4 proximal 
tubules has also been reported to be 
localized to the brush border. 15 
 The mouse ischemia – reperfusion 
 studies by Hotta  et al. 13 used unilateral 
ischemia of 30  minutes ’ duration with 
simultaneous contralateral nephrectomy 
but were done at 32 – 33 ° C, which will have 
signifi cantly mitigated the insult. Th e net 
functional change in the male C57BL / 6 
mice studied was moderately severe, with 
average blood urea nitrogen of 126 and 
creatinine of 0.54 in unprotected mice at 
24 hours. Treatment 1  h before ischemia 
with an anti-Fn14 blocking monoclonal 
antibody, ITEM-2, lowered these values 
by about 50 % and reduced histological 
damage, TUNEL-positive cells, and 
neutro phil and macrophage infi ltration, 
as well as cytokine and chemokine pro-
duction. Pre treatment with ITEM-2 signi-
fi cantly decreased fi brosis that developed 
during 30 days after the insult and 
increased 7-day survival in mice that 
were subjected to a longer period of 
ischemia that produced substantial mor-
tality. Hotta  et al. 13 in this work also 
show that ITEM-2 blocks cytokine pro-
duction by cultured tubule cells subjected 
to a brief period of hypoxia. 
 In aggregate, the earlier data for folate 
nephropathy and the present observa-
tions indicate an important role for Fn14 
during acute kidney injury, including the 
extensively studied clamp ischemia set-
ting. Furthermore, this study adds to the 
evidence for involvement of TWEAK –
 Fn14 in human disease. Th e data support 
the concept of a paracrine and autocrine 
loop in which TWEAK produced by 
tubule cells feeds back on them via the 
upregulated Fn14 receptors expressed 
downstream in the proximal tubule, 
where cells are more injured ( Figure 1 ). 
Th e magnitude of the eff ect of blocking 
Fn14 would seem to indicate that 
TWEAK may be as important as the 
other cytokines, TNF-  and Fas ligand, 
that act similarly and possibly in a coor-
dinate fashion. 
 Hotta  et al. 13 have not assessed TWEAK 
and Fn14 in infl ammatory and vascular 
cells, where they are also expressed and 
would be subject to modulation by sys-
temic administration of ITEM-2. But their 
work and the prior studies by Ortiz and co-
workers 5,7 indicate that eff ects of TWEAK –
 Fn14 sufficient to account for all the 
observed behavior  in vivo are seen in cul-
tured tubule cells. Also relevant in this 
regard, work using chimeric mice has 
shown that the Fn14 on resident kidney 
cells, but not that on bone marrow-derived 
cells, contributes to progression in a lupus 
nephritis model. 8 
 Although TWEAK – Fn14 modulates 
proliferation and chronic infl ammatory 
processes in addition to promoting apop-
tosis and acute infl ammation, 2,3,6,7 the 
behavior observed by Hotta  et al. 13 likely 
predominantly reflects modulation of 
early events and primary cell injury rather 
than repair, since increases of Fn14 
occurred rapidly within the fi rst 24 hours 
and strongly ameliorated functional dete-
rioration and structural damage occur-
ring within that period. Th e eff ects on 
survival at 7 days and fi brosis at 30 days 
likely refl ect the initial amelioration of 
injury rather than any ongoing benefi t of 
suppression of the system. Studies of 
delayed administration of ITEM-2 will be 
required to assess this important issue. 
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 Figure 1  |  Tubule cell TWEAK – Fn14 interactions during acute kidney injury. Based on the work of Hotta  et al. 13 and previous studies by Ortiz and 
co-workers, 5,6 a mechanism can be envisioned wherein soluble TWEAK (sT) is produced in tubule cells upstream and locally interacts with upregulated 
apical Fn14 receptors in the S3 segment tubules of the outer medulla to induce production of inflammatory mediators and, in the presence of other 
cytokines, cell death during early injury. Proliferative effects would occur later in surviving cells. IFN-  , interferon-  ; NF-  B, nuclear factor-  B; TNF-  , 
tumor necrosis factor-  . 
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